Modulation of Cellular Biochemistry, Epigenetics and Metabolomics by Ketone Bodies. Implications of the Ketogenic Diet in the Physiology of the Organism and Pathological States

Arkadiusz Dąbek, Martyna Wojtala, Luciano Pirola, Aneta Balcerczyk, Arkadiusz Dąbek, Martyna Wojtala, Luciano Pirola, Aneta Balcerczyk

Abstract

Ketone bodies (KBs), comprising β-hydroxybutyrate, acetoacetate and acetone, are a set of fuel molecules serving as an alternative energy source to glucose. KBs are mainly produced by the liver from fatty acids during periods of fasting, and prolonged or intense physical activity. In diabetes, mainly type-1, ketoacidosis is the pathological response to glucose malabsorption. Endogenous production of ketone bodies is promoted by consumption of a ketogenic diet (KD), a diet virtually devoid of carbohydrates. Despite its recently widespread use, the systemic impact of KD is only partially understood, and ranges from physiologically beneficial outcomes in particular circumstances to potentially harmful effects. Here, we firstly review ketone body metabolism and molecular signaling, to then link the understanding of ketone bodies' biochemistry to controversies regarding their putative or proven medical benefits. We overview the physiological consequences of ketone bodies' consumption, focusing on (i) KB-induced histone post-translational modifications, particularly β-hydroxybutyrylation and acetylation, which appears to be the core epigenetic mechanisms of activity of β-hydroxybutyrate to modulate inflammation; (ii) inflammatory responses to a KD; (iii) proven benefits of the KD in the context of neuronal disease and cancer; and (iv) consequences of the KD's application on cardiovascular health and on physical performance.

Keywords: cancer; epigenetics; inflammatory response; ketogenic diet; ketone bodies; β-hydroxybutyrate.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Metabolism of ketone bodies. (A) Synthesis of ketone bodies in the liver mitochondria. (B/C) Alternative metabolic fates of ketone bodies. (B) Funneling in the Krebs via succinyl-CoA:3-ketoacid coenzyme A transferase (SCOT) in mitochondria of extrahepatic tissues, and (C) their being used as metabolic precursors in cholesterol synthesis or de novo lipogenesis.
Figure 2
Figure 2
The epigenetic effect of ketone bodies on chromatin status. Pathways of modification of chromatin conformation by ketone bodies through histone posttranslational modifications (PTMs): (i) increasing the pool of acetyl-CoA as substrate for HATs, (ii) inducing changes methylation status of histones and (iii) causing β-hydroxybutyrylation per se or hyperacetylation with β-hydroxybutyrate acting as a histone deacetylase inhibitor.
Figure 3
Figure 3
Selective use of ketone bodies by normal, non-cancerous cells can allow bypassing the glucose-induced Warburg effect in cancer cells. (A) In normal cells, glucose is fully oxidized through glycolysis followed by the mitochondrial Krebs cycle coupled to oxidative phosphorylation. (C) In cancer cells, pyruvate (the last metabolic intermediate of glycolysis) is reduced to lactate, which may serve as a precursor to sustain biosynthetic pathways. (B,D) Under conditions of glucose depletion, insulin deficiency, ketogenic diet or prolonged intensive physical activity, glucose becomes limited and cells resort to the use of ketone bodies, including BHB. (B) In normal cells, BHB can sustain extra mitochondrial biosynthetic pathways and serve as a AcCoA source to feed the Krebs cycle. (D) In cancer cells, the replacement of glucose as the primary energy source with ketone bodies (BHB) enables blunting the Warburg effect and tumor cell growth. (GLUT, glucose transporter; MCT monocarboxylate transporter; OxPhos, oxidative phosphorylation; SCOT, Succinyl-CoA: 3-ketoacid CoA transferase; ROS, reactive oxygen species; AcAc, acetoacetate).

References

    1. Puchalska P., Crawford P.A. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017;25:262–284. doi: 10.1016/j.cmet.2016.12.022.
    1. Gershuni V.M., Yan S.L., Medici V. Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome. Curr. Nutr. Rep. 2018;7:97–106. doi: 10.1007/s13668-018-0235-0.
    1. Hashim S.A., VanItallie T.B. Ketone body therapy: From the ketogenic diet to the oral administration of ketone ester. J. Lipid Res. 2014;55:1818–1826. doi: 10.1194/jlr.R046599.
    1. O’Neill B., Raggi P. The ketogenic diet: Pros and cons. Atherosclerosis. 2019;292:119–126. doi: 10.1016/j.atherosclerosis.2019.11.021.
    1. Henderson C.B., Filloux F.M., Alder S.C., Lyon J.L., Caplin D.A. Efficacy of the Ketogenic Diet as a Treatment Option for Epilepsy: Meta-Analysis. J. Child. Neurol. 2006;21:193–198.
    1. Castellana M., Conte E., Cignarelli A., Perrini S., Giustina A., Giovanella L., Giorgino F., Trimboli P. Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 2020 doi: 10.1007/s11154-019-09514-y.
    1. Westman E.C., Feinman R.D., Mavropoulos J.C., Vernon M.C., Volek J.S., Wortman J.A., Yancy W.S., Phinney S.D. Low-carbohydrate nutrition and metabolism. Am. J. Clin. Nutr. 2007;86:276–284. doi: 10.1093/ajcn/86.2.276.
    1. Achanta L.B., Rae C.D. β-Hydroxybutyrate in the Brain: One Molecule, Multiple Mechanisms. Neurochem. Res. 2017;42:35–49. doi: 10.1007/s11064-016-2099-2.
    1. Anderson A.J., Dawes E.A. Occurrence, metabolism, metabolic role, and industrial uses of bacterial polyhydroxyalkanoates. Microbiol. Rev. 1990;54:450–472. doi: 10.1128/MMBR.54.4.450-472.1990.
    1. Dedkova E.N., Blatter L.A. Role of β-hydroxybutyrate, its polymer poly-β-hydroxybutyrate and inorganic polyphosphate in mammalian health and disease. Front. Physiol. 2014;5:260. doi: 10.3389/fphys.2014.00260.
    1. Smithen M., Elustondo P.A., Winkfein R., Zakharian E., Abramov A.Y., Pavlov E. Role of polyhydroxybutyrate in mitochondrial calcium uptake. Cell Calcium. 2013;54:86–94. doi: 10.1016/j.ceca.2013.04.006.
    1. Elustondo P.A., Angelova P.R., Kawalec M., Michalak M., Kurcok P., Abramov A.Y., Pavlov E.V. Polyhydroxybutyrate targets mammalian mitochondria and increases permeability of plasmalemmal and mitochondrial membranes. PLoS ONE. 2013;8:e75812. doi: 10.1371/journal.pone.0075812.
    1. Auestad N., Korsak R.A., Morrow J.W., Edmond J. Fatty acid oxidation and ketogenesis by astrocytes in primary culture. J. Neurochem. 1991;56:1376–1386. doi: 10.1111/j.1471-4159.1991.tb11435.x.
    1. Cheng C.-W., Biton M., Haber A.L., Gunduz N., Eng G., Gaynor L.T., Tripathi S., Calibasi-Kocal G., Rickelt S., Butty V.L., et al. Ketone Body Signaling Mediates Intestinal Stem Cell Homeostasis and Adaptation to Diet. Cell. 2019;178:1115–1131. doi: 10.1016/j.cell.2019.07.048.
    1. Zhang H., Tang K., Ma J., Zhou L., Liu J., Zeng L., Zhu L., Xu P., Chen J., Wei K., et al. Ketogenesis-generated β-hydroxybutyrate is an epigenetic regulator of CD8+ T-cell memory development. Nat. Cell Biol. 2020;22:18–25. doi: 10.1038/s41556-019-0440-0.
    1. Longo V.D., Mattson M.P. Fasting: Molecular mechanisms and clinical applications. Cell Metab. 2014;19:181–192. doi: 10.1016/j.cmet.2013.12.008.
    1. Halestrap A.P., Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 2004;447:619–628. doi: 10.1007/s00424-003-1067-2.
    1. Pierre K., Pellerin L. Monocarboxylate transporters in the central nervous system: Distribution, regulation and function. J. Neurochem. 2005;94:1–14. doi: 10.1111/j.1471-4159.2005.03168.x.
    1. Laffel L. Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab. Res. Rev. 1999;15:412–426. doi: 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>;2-8.
    1. Saudubray J.M., Marsac C., Limal J.M., Dumurgier E., Charpentier C., Ogier H., Coudè F.X. Variation in plasma ketone bodies during a 24-hour fast in normal and in hypoglycemic children: relationship to age. J. Pediatr. 1981;98:904–908. doi: 10.1016/S0022-3476(81)80583-5.
    1. Rehni A.K., Dave K.R. Impact of Hypoglycemia on Brain Metabolism During Diabetes. Mol. Neurobiol. 2018;55:9075–9088. doi: 10.1007/s12035-018-1044-6.
    1. Takahashi Y., Terada S., Banjo M., Seike K., Nakano S., Hatta H. Effects of β-hydroxybutyrate treatment on glycogen repletion and its related signaling cascades in epitrochlearis muscle during 120 min of postexercise recovery. Appl. Physiol. Nutr. Metab. 2019;44:1311–1319. doi: 10.1139/apnm-2018-0860.
    1. Boison D. New insights into the mechanisms of the ketogenic diet. Curr. Opin. Neurol. 2017;30:187–192. doi: 10.1097/WCO.0000000000000432.
    1. Ruan H.-B., Crawford P.A. Ketone bodies as epigenetic modifiers. Curr. Opin. Clin. Nutr. Metab. Care. 2018;21:260–266. doi: 10.1097/MCO.0000000000000475.
    1. Xie Z., Zhang D., Chung D., Tang Z., Huang H., Dai L., Qi S., Li J., Colak G., Chen Y., et al. Metabolic Regulation of Gene Expression by Histone Lysine β-Hydroxybutyrylation. Mol. Cell. 2016;62:194–206. doi: 10.1016/j.molcel.2016.03.036.
    1. Liu K., Li F., Sun Q., Lin N., Han H., You K., Tian F., Mao Z., Li T., Tong T., et al. p53 β-hydroxybutyrylation attenuates p53 activity. Cell Death Dis. 2019;10:243. doi: 10.1038/s41419-019-1463-y.
    1. Chen L., Miao Z., Xu X. β-hydroxybutyrate alleviates depressive behaviors in mice possibly by increasing the histone3-lysine9-β-hydroxybutyrylation. Biochem. Biophys. Res. Commun. 2017;490:117–122. doi: 10.1016/j.bbrc.2017.05.184.
    1. Fan J., Krautkramer K.A., Feldman J.L., Denu J.M. Metabolic regulation of histone post-translational modifications. ACS Chem. Biol. 2015;10:95–108. doi: 10.1021/cb500846u.
    1. Shimazu T., Hirschey M.D., Newman J., He W., Shirakawa K., Le Moan N., Grueter C.A., Lim H., Saunders L.R., Stevens R.D., et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339:211–214. doi: 10.1126/science.1227166.
    1. Newman J.C., Covarrubias A.J., Zhao M., Yu X., Gut P., Ng C.-P., Huang Y., Haldar S., Verdin E. Ketogenic Diet Reduces Midlife Mortality and Improves Memory in Aging Mice. Cell Metab. 2017;26:547–557. doi: 10.1016/j.cmet.2017.08.004.
    1. Chriett S., Dąbek A., Wojtala M., Vidal H., Balcerczyk A., Pirola L. Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci. Rep. 2019;9:742. doi: 10.1038/s41598-018-36941-9.
    1. Cambronne X.A., Stewart M.L., Kim D., Jones-Brunette A.M., Morgan R.K., Farrens D.L., Cohen M.S., Goodman R.H. Biosensor reveals multiple sources for mitochondrial NAD+ Science. 2016;352:1474–1477. doi: 10.1126/science.aad5168.
    1. Masino S.A., Li T., Theofilas P., Sandau U.S., Ruskin D.N., Fredholm B.B., Geiger J.D., Aronica E., Boison D. A ketogenic diet suppresses seizures in mice through adenosine A₁ receptors. J. Clin. Investig. 2011;121:2679–2683. doi: 10.1172/JCI57813.
    1. Lusardi T.A., Akula K.K., Coffman S.Q., Ruskin D.N., Masino S.A., Boison D. Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. Neuropharmacology. 2015;99:500–509. doi: 10.1016/j.neuropharm.2015.08.007.
    1. Kobow K., Kaspi A., Harikrishnan K.N., Kiese K., Ziemann M., Khurana I., Fritzsche I., Hauke J., Hahnen E., Coras R., et al. Deep sequencing reveals increased DNA methylation in chronic rat epilepsy. Acta Neuropathol. 2013;126:741–756. doi: 10.1007/s00401-013-1168-8.
    1. Shyh-Chang N., Locasale J.W., Lyssiotis C.A., Zheng Y., Teo R.Y., Ratanasirintrawoot S., Zhang J., Onder T., Unternaehrer J.J., Zhu H., et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science. 2013;339:222–226. doi: 10.1126/science.1226603.
    1. Gietzen D.W., Lindström S.H., Sharp J.W., Teh P.S., Donovan M.J. Indispensable Amino Acid-Deficient Diets Induce Seizures in Ketogenic Diet-Fed Rodents, Demonstrating a Role for Amino Acid Balance in Dietary Treatments for Epilepsy. J. Nutr. 2018;148:480–489. doi: 10.1093/jn/nxx030.
    1. Kashiwaya Y., Takeshima T., Mori N., Nakashima K., Clarke K., Veech R.L. D-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc. Natl. Acad. Sci. USA. 2000;97:5440–5444. doi: 10.1073/pnas.97.10.5440.
    1. Fu S.-P., Li S.-N., Wang J.-F., Li Y., Xie S.-S., Xue W.-J., Liu H.-M., Huang B.-X., Lv Q.-K., Lei L.-C., et al. BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-κB activation. Mediators Inflamm. 2014;2014:983401. doi: 10.1155/2014/983401.
    1. Kong G., Huang Z., Ji W., Wang X., Liu J., Wu X., Huang Z., Li R., Zhu Q. The Ketone Metabolite β-Hydroxybutyrate Attenuates Oxidative Stress in Spinal Cord Injury by Suppression of Class I Histone Deacetylases. J. Neurotrauma. 2017;34:2645–2655. doi: 10.1089/neu.2017.5192.
    1. Swerdlow R.H. Brain aging, Alzheimer’s disease, and mitochondria. Biochim. Biophys. Acta. 2011;12:1630–1639. doi: 10.1016/j.bbadis.2011.08.012.
    1. Wilkins H.M., Swerdlow R.H. Amyloid precursor protein processing and bioenergetics. Brain Res. Bull. 2017;133:71–79. doi: 10.1016/j.brainresbull.2016.08.009.
    1. Kashiwaya Y., Bergman C., Lee J.H., Wan R., King M.T., Mughal M.R., Okun E., Clarke K., Mattson M.P., Veech R.L. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer’s disease. Neurobiol. Aging. 2013;34:1530–1539. doi: 10.1016/j.neurobiolaging.2012.11.023.
    1. Van der Auwera I., Wera S., Van Leuven F., Henderson S.T. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease. Nutr. Metab. Lond. 2005;2:28. doi: 10.1186/1743-7075-2-28.
    1. Sullivan P.G., Rippy N.A., Dorenbos K., Concepcion R.C., Agarwal A.K., Rho J.M. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann. Neurol. 2004;55:576–580. doi: 10.1002/ana.20062.
    1. Brownlow M.L., Benner L., D’Agostino D., Gordon M.N., Morgan D. Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer’s pathology. PLoS ONE. 2013;8:e75713. doi: 10.1371/journal.pone.0075713.
    1. Reger M.A., Henderson S.T., Hale C., Cholerton B., Baker L.D., Watson G.S., Hyde K., Chapman D., Craft S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol. Aging. 2004;25:311–314. doi: 10.1016/S0197-4580(03)00087-3.
    1. Henderson S.T., Vogel J.L., Barr L.J., Garvin F., Jones J.J., Costantini L.C. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: A randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. Lond. 2009;6:31. doi: 10.1186/1743-7075-6-31.
    1. Rebello C.J., Keller J.N., Liu A.G., Johnson W.D., Greenway F.L. Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: A randomized controlled trial. BBA Clin. 2015;3:123–125. doi: 10.1016/j.bbacli.2015.01.001.
    1. Ota M., Matsuo J., Ishida I., Takano H., Yokoi Y., Hori H., Yoshida S., Ashida K., Nakamura K., Takahashi T., et al. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer’s disease. Neurosci. Lett. 2019;690:232–236. doi: 10.1016/j.neulet.2018.10.048.
    1. Yu Y., Yu Y., Zhang Y., Zhang Z., An W., Zhao X. Treatment with D-β-hydroxybutyrate protects heart from ischemia/reperfusion injury in mice. Eur. J. Pharmacol. 2018;829:121–128. doi: 10.1016/j.ejphar.2018.04.019.
    1. Suzuki M., Suzuki M., Sato K., Dohi S., Sato T., Matsuura A., Hiraide A. Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn. J. Pharmacol. 2001;87:143–150. doi: 10.1254/jjp.87.143.
    1. Zou Z., Sasaguri S., Rajesh K.G., Suzuki R. dl-3-Hydroxybutyrate administration prevents myocardial damage after coronary occlusion in rat hearts. Am. J. Physiol. Heart Circ. Physiol. 2002;283:H1968–H1974. doi: 10.1152/ajpheart.00250.2002.
    1. Godar R.J., Ma X., Liu H., Murphy J.T., Weinheimer C.J., Kovacs A., Crosby S.D., Saftig P., Diwan A. Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. Autophagy. 2015;11:1537–1560. doi: 10.1080/15548627.2015.1063768.
    1. Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Collins K.J., Dennison Himmelfarb C., DePalma S.M., Gidding S., Jamerson K.A., Jones D.W., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115.
    1. Kjeldsen S.E. Hypertension and cardiovascular risk: General aspects. Pharmacol. Res. 2018;129:95–99. doi: 10.1016/j.phrs.2017.11.003.
    1. Walkowska A., Kuczeriszka M., Sadowski J., Olszyñski K.H., Dobrowolski L., Červenka L., Hammock B.D., Kompanowska-Jezierska E. High salt intake increases blood pressure in normal rats: putative role of 20-HETE and no evidence on changes in renal vascular reactivity. Kidney Blood Press. Res. 2015;40:323–334. doi: 10.1159/000368508.
    1. Chakraborty S., Galla S., Cheng X., Yeo J.-Y., Mell B., Singh V., Yeoh B., Saha P., Mathew A.V., Vijay-Kumar M., et al. Salt-Responsive Metabolite, β-Hydroxybutyrate, Attenuates Hypertension. Cell Rep. 2018;25:677–689. doi: 10.1016/j.celrep.2018.09.058.
    1. Cox P.J., Clarke K. Acute nutritional ketosis: Implications for exercise performance and metabolism. Extrem. Physiol. Med. 2014;3:17. doi: 10.1186/2046-7648-3-17.
    1. Vandenberghe C., St-Pierre V., Fortier M., Castellano C.A., Cuenoud B., Cunnane S.C. Medium Chain Triglycerides Modulate the Ketogenic Effect of a Metabolic Switch. Front. Nutr. 2020;7:3. doi: 10.3389/fnut.2020.00003.
    1. Kiens B., Astrup A. Ketogenic Diets for Fat Loss and Exercise Performance: Benefits and Safety? Exerc. Sport Sci. Rev. 2015;43:109. doi: 10.1249/JES.0000000000000053.
    1. Fleming J., Sharman M.J., Avery N.G., Love D.M., Gómez A.L., Scheett T.P., Kraemer W.J., Volek J.S. Endurance capacity and high-intensity exercise performance responses to a high fat diet. Int. J. Sport Nutr. Exerc. Metab. 2003;13:466–478. doi: 10.1123/ijsnem.13.4.466.
    1. Cox P.J., Kirk T., Ashmore T., Willerton K., Evans R., Smith A., Murray A.J., Stubbs B., West J., McLure S.W., et al. Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes. Cell Metab. 2016;24:256–268. doi: 10.1016/j.cmet.2016.07.010.
    1. Phinney S.D., Bistrian B.R., Evans W.J., Gervino E., Blackburn G.L. The human metabolic response to chronic ketosis without caloric restriction: Preservation of submaximal exercise capability with reduced carbohydrate oxidation. Metab. Clin. Exp. 1983;32:769–776. doi: 10.1016/0026-0495(83)90106-3.
    1. Volek J.S., Freidenreich D.J., Saenz C., Kunces L.J., Creighton B.C., Bartley J.M., Davitt P.M., Munoz C.X., Anderson J.M., Maresh C.M., et al. Metabolic characteristics of keto-adapted ultra-endurance runners. Metab. Clin. Exp. 2016;65:100–110. doi: 10.1016/j.metabol.2015.10.028.
    1. Miller W.C., Bryce G.R., Conlee R.K. Adaptations to a high-fat diet that increase exercise endurance in male rats. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1984;56:78–83. doi: 10.1152/jappl.1984.56.1.78.
    1. Goedecke J.H., Christie C., Wilson G., Dennis S.C., Noakes T.D., Hopkins W.G., Lambert E.V. Metabolic adaptations to a high-fat diet in endurance cyclists. Metab. Clin. Exp. 1999;48:1509–1517. doi: 10.1016/S0026-0495(99)90238-X.
    1. Gibson A.A., Seimon R.V., Lee C.M.Y., Ayre J., Franklin J., Markovic T.P., Caterson I.D., Sainsbury A. Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. Obes. Rev. 2015;16:64–76. doi: 10.1111/obr.12230.
    1. Lambert E.V., Speechly D.P., Dennis S.C., Noakes T.D. Enhanced endurance in trained cyclists during moderate intensity exercise following 2 weeks adaptation to a high fat diet. Eur. J. Appl. Physiol. Occup. Physiol. 1994;69:287–293. doi: 10.1007/BF00392032.
    1. Zajac A., Poprzecki S., Maszczyk A., Czuba M., Michalczyk M., Zydek G. The effects of a ketogenic diet on exercise metabolism and physical performance in off-road cyclists. Nutrients. 2014;6:2493–2508. doi: 10.3390/nu6072493.
    1. Sansone M., Sansone A., Borrione P., Romanelli F., Di Luigi L., Sgrò P. Effects of Ketone Bodies on Endurance Exercise. Curr. Sports Med. Rep. 2018;17:444–453. doi: 10.1249/JSR.0000000000000542.
    1. Evans M., Cogan K.E., Egan B. Metabolism of ketone bodies during exercise and training: Physiological basis for exogenous supplementation. J. Physiol. 2017;595:2857–2871. doi: 10.1113/JP273185.
    1. Epstein T., Gatenby R.A., Brown J.S. The Warburg effect as an adaptation of cancer cells to rapid fluctuations in energy demand. PLoS ONE. 2017;12:e0185085. doi: 10.1371/journal.pone.0185085.
    1. Martinez-Outschoorn U.E., Lin Z., Trimmer C., Flomenberg N., Wang C., Pavlides S., Pestell R.G., Howell A., Sotgia F., Lisanti M.P. Cancer cells metabolically “fertilize” the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: Implications for PET imaging of human tumors. Cell Cycle. 2011;10:2504–2520. doi: 10.4161/cc.10.15.16585.
    1. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578. doi: 10.1016/S0140-6736(08)60269-X.
    1. Khodadadi S., Sobhani N., Mirshekar S., Ghiasvand R., Pourmasoumi M., Miraghajani M., Dehsoukhteh S.S. Tumor Cells Growth and Survival Time with the Ketogenic Diet in Animal Models: A Systematic Review. Int. J. Prev. Med. 2017;8:35.
    1. Aminzadeh-Gohari S., Feichtinger R.G., Vidali S., Locker F., Rutherford T., O’Donnel M., Stöger-Kleiber A., Mayr J.A., Sperl W., Kofler B. A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model. Oncotarget. 2017;8:64728–64744. doi: 10.18632/oncotarget.20041.
    1. Weber D.D., Aminzadeh-Gohari S., Tulipan J., Catalano L., Feichtinger R.G., Kofler B. Ketogenic diet in the treatment of cancer—Where do we stand? Mol. Metab. 2020;33:102–121. doi: 10.1016/j.molmet.2019.06.026.
    1. Weber D.D., Aminazdeh-Gohari S., Kofler B. Ketogenic diet in cancer therapy. Aging. 2018;10:164–165. doi: 10.18632/aging.101382.
    1. Xia S., Lin R., Jin L., Zhao L., Kang H.-B., Pan Y., Liu S., Qian G., Qian Z., Konstantakou E., et al. Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metab. 2017;25:358–373. doi: 10.1016/j.cmet.2016.12.010.
    1. Klement R.J. Beneficial effects of ketogenic diets for cancer patients: A realist review with focus on evidence and confirmation. Med. Oncol. 2017;34:132. doi: 10.1007/s12032-017-0991-5.
    1. Buchhalter J.R., D’Alfonso S., Connolly M., Fung E., Michoulas A., Sinasac D., Singer R., Smith J., Singh N., Rho J.M. The relationship between d-beta-hydroxybutyrate blood concentrations and seizure control in children treated with the ketogenic diet for medically intractable epilepsy. Epilepsia Open. 2017;2:317–321. doi: 10.1002/epi4.12058.
    1. Neal E.G., Chaffe H., Schwartz R.H., Lawson M.S., Edwards N., Fitzsimmons G., Whitney A., Cross J.H. The ketogenic diet for the treatment of childhood epilepsy: A randomised controlled trial. Lancet Neurol. 2008;7:500–506. doi: 10.1016/S1474-4422(08)70092-9.
    1. Lambrechts D.A., de Kinderen R.J., Vles J.S., de Louw A.J., Aldenkamp A.P., Majoie H.J. A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurol. Scand. 2017;135:231–239. doi: 10.1111/ane.12592.
    1. Kang H.C., Kim Y.J., Kim D.W., Kim H.D. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia. 2005;46:272–279. doi: 10.1111/j.0013-9580.2005.48504.x.
    1. Dressler A., Stöcklin B., Reithofer E., Benninger F., Freilinger M., Hauser E., Reiter-Fink E., Seidl R., Trimmel-Schwahofer P., Feucht M. Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy—the Austrian experience. Seizure. 2010;19:404–408. doi: 10.1016/j.seizure.2010.06.006.
    1. De Cabo R., Mattson M.P. Effects of Intermittent Fasting on Health, Aging, and Disease. N. Engl. J. Med. 2019;381:2541–2551. doi: 10.1056/NEJMra1905136.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere